loading...

Birmingham Vasculitis Activity Score for Wegener’s Granulomatosis (BVAS-WG)

Stone JH; Hoffman GS; Merkel PA; Min YI; Uhlfelder ML; Hellmann DB; Specks U; Allen NB; Davis JC; Spiera RF; Calabrese LH; Wigley FM; Maiden N; Valente RM; Niles JL; Fye KH; McCune JW; St Clair EW; Luqmani RA

Distributed by Mapi Research Trust

ProQolid

Distributed by Mapi Research Trust

Basic description

Developed in 1999; Derived from the Birmingham Vasculitis Activity Score developed in 1994

Authors

Stone JH; Hoffman GS; Merkel PA; Min YI; Uhlfelder ML; Hellmann DB; Specks U; Allen NB; Davis JC; Spiera RF; Calabrese LH; Wigley FM; Maiden N; Valente RM; Niles JL; Fye KH; McCune JW; St Clair EW; Luqmani RA

Copyright
© 2001, American College of Rheumatology, managed by Wiley
Objective
To capture disease manifestations relevant to Wegener Granulomatosis
Therapeutic area
  • Cardiovascular Diseases
  • Respiratory Tract Diseases
  • Immune System Diseases
  • Rare disease (Orphanet definition)
Therapeutic indication

Granulomatosis with Polyangiitis For more information on this rare disease, please consult the following link: Orphanet page

Type of Clinical Outcome Assessment (COA)
  • clinro ClinRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, Specks U, Allen NB, Davis JC, Spiera RF, Calabrese LH, Wigley FM, Maiden N, Valente RM, Niles JL, Fye KH, McCune JW, St Clair EW, Luqmani RA; International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum. 2001 Apr;44(4):912-20 (Wiley Online Library)

Access this questionnaire

Original content as well as existing translations are licensed by and can be obtained from Mapi Research Trust on behalf of Wiley as per the following process:

Academic users, Individual Practitioners (no funding)

You may access the questionnaire and/or its available translations directly online (see tutorial). Should you not see the Download button, please contact us.

Funded academic users, healthcare organizations, commercial users & IT companies

Fees may apply to your project. Submit your request (see tutorial). Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.


Contact and conditions of use

Authors

Stone JH; Hoffman GS; Merkel PA; Min YI; Uhlfelder ML; Hellmann DB; Specks U; Allen NB; Davis JC; Spiera RF; Calabrese LH; Wigley FM; Maiden N; Valente RM; Niles JL; Fye KH; McCune JW; St Clair EW; Luqmani RA

Stone John, MD

MPH Director, Clinical Rheumatology,

MGH Associate Professor of Medicine, Division of Rheumatology, Harvard Medical School

MGH Academy

1 Bowdoin Sq, Ste 700

Boston, MA 02114

USA

Stone Publications (PubMed)

Contact information

Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66

Conditions of use

Original content as well as existing translations are licensed by and can be obtained from Mapi Research Trust on behalf of Wiley as per the following process:

Academic users, Individual Practitioners (no funding)

You may access the questionnaire and/or its available translations directly online (see tutorial). Should you not see the Download button, please contact us.

Funded academic users, healthcare organizations, commercial users & IT companies

Fees may apply to your project. Submit your request (see tutorial). Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.

Available on the CanVasc Website

Languages

Original language(s)

  • English for the USA

Translations

The list of available translations is subject to constant changes and may not be exhaustive. It is provided for information only. Some recently produced translations may not be included in the list below yet. Please do check the status of available translations with Mapi Research Trust / the developers / copyright holders / distributors.

Also, the listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.

BVAS-WG

French

Wiley has selected Mapi Research Trust as exclusive coordinator for the linguistic validation of the COA to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi/ICON Language Services

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.

More information on translations

French adaptation available on the CanVasc Website

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us